论文部分内容阅读
目的:探讨MCM2在宫颈癌和癌前病变中的表达及其临床意义。方法:选择宫颈液基细胞学剩余标本进行MCM2免疫细胞化学标记,MCM2标记结果与细胞学结果和活检组织学结果对照分析。结果:共收集了187例宫颈液基细胞学剩余标本,其中172例有活检组织学结果。MCM2在细胞学诊断的SCC、HSIL、LSIL、ASC-H和ASC-US中阳性表达率分别为100.0%、97.1%、68.1%、100.0%和54.6%,在活检组织学确诊的SCC、CIN3、CIN2和CIN1中阳性表达率分别为100.0%、92.2%、75.0%和85.7%。在40例非典型鳞状上皮细胞(ASC)中,MCM2检测对筛选组织学确诊的CIN1及以上病变敏感性和特异性分别为85.7%和80.0%;对筛选CIN2及以上病变的敏感性和特异性分别为77.8%和86.7%。结论:MCM2在宫颈癌和癌前病变中高表达,并可作为宫颈癌筛查和ASC管理的辅助性标志。
Objective: To investigate the expression of MCM2 in cervical cancer and precancerous lesions and its clinical significance. Methods: The remaining specimens of cervical liquid-based cytology were selected for immunocytochemical labeling of MCM2. The results of MCM2 labeling were compared with those of cytology and biopsy. RESULTS: A total of 187 cervical cytology-based cytology specimens were collected, of which 172 had biopsy histological findings. The positive rates of MCM2 in cytological diagnosis of SCC, HSIL, LSIL, ASC-H and ASC-US were 100.0%, 97.1%, 68.1%, 100.0% and 54.6% The positive rates of CIN2 and CIN1 were 100.0%, 92.2%, 75.0% and 85.7% respectively. In 40 cases of atypical squamous cell (ASC), the sensitivity and specificity of MCM2 detection in screening histologically confirmed CIN1 and above lesions were 85.7% and 80.0%, respectively. The sensitivity and specificity of screening MCA2 and above lesions Sexuality was 77.8% and 86.7% respectively. Conclusion: MCM2 is highly expressed in cervical cancer and precancerous lesions, and can be used as a secondary marker of cervical cancer screening and ASC management.